5 January 2010 - Ark Therapeutics Group plc, announces that it has filed the formal request to the European Medicines Agency (EMEA) for re-examination of its marketing authorization application (MAA) for Cerepro®, Ark's novel gene-based therapy for operable malignant glioma (brain cancer).
the details can be read here.
No comments:
Post a Comment